(MedPage Today) -- Blood level monitoring and dose adjustment for dabigatran (Pradaxa) could reduce major bleeding risk by 40% compared with well-controlled warfarin, according to company documents allegedly hidden from physicians and regulators. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment